An update on small molecules targeting CXCR4 as starting points for the development of anti-cancer therapeutics
Author:
Publisher
Elsevier BV
Subject
Organic Chemistry,Drug Discovery,Pharmacology,General Medicine
Reference63 articles.
1. Agonists for the chemokine receptor CXCR4;Lefrancois;ACS Med. Chem. Lett.,2011
2. Chemokine: receptor structure, interactions, and antagonism;Allen;Annu. Rev. Immunol.,2007
3. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists;Wu;Science,2010
4. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry;Bleul;Nature,1996
5. Highly specific and sensitive pharmacophore model for identifying CXCR4 antagonists. Comparison with docking and shape-matching virtual screening performance;Karaboga;J. Chem. Inf. Model.,2013
Cited by 35 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. trans-IV restriction: a new configuration for metal bis-cyclam complexes as potent CXCR4 inhibitors;Dalton Transactions;2024
2. Recent advancement in pyrrolidine moiety for the management of cancer: A review;Results in Chemistry;2024-01
3. Discovery of Bis-Imidazoline Derivatives as New CXCR4 Ligands;Molecules;2023-01-24
4. Structural dynamics of chemokine receptors;Vitamins and Hormones;2023
5. Chemokines and NSCLC: Emerging role in prognosis, heterogeneity, and therapeutics;Seminars in Cancer Biology;2022-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3